Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 35 of 102, showing 5 Applications out of 509 total, starting on record 171, ending on 175

# Protocol No Study Title Investigator(s) & Site(s)

171.

ECCT/22/10/05   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Videlis N Nduba
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View

172.

ECCT/23/11/06   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. AHERO CLINICAL TRIALS UNIT (Kisumu county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
 
View

173.

ECCT/23/09/03   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Simon Kariuki
Site(s) in Kenya
1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county)
 
View

174.

ECCT/24/04/08   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Wilson Muraya
Site(s) in Kenya
1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county)
 
View

175.

ECCT/24/05/01   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Videlis Nduba
Site(s) in Kenya
1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county)
 
View